0.04
-5.26%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zoono Group
Its shares trade on ASX under the ticker ZNO.AX. It has been listed since 21 July 1988. In the fiscal year to 30 June 2026, it reported revenue of NZD 1.5m and a net loss of NZD 1.6m. At that date it held total assets of NZD 5.3m and shareholders' equity of NZD 2.9m.
Zoono Group Ltd. is a pharmaceutical and biotechnology company. The company is headquartered in Sydney, New South Wales. The firm has developed Zoono Molecule. Zoono Molecule is an antimicrobial that bonds to any surface, including hard surfaces, textiles, fabrics, and skin. Zoono Molecule kills pathogens, including bacteria, viruses, algae, fungi and mould. Its products include Hand Sanitiser GermFree24, Zoono SkinClear, Zoono Foot Guard, Odor Guard, Bathroom Microbe Shield, Kitchen Microbe Shield, Sport Microbe Shield, All Purpose Microbe Shield, Wet Wipes, Zoono Z-71 Surface Sanitiser, ZoonoTex Z-35 Textile Treatment, Zoono Deodorant, Zoono Mould Guard, Zoono Ultra, Zoono Aerosol, Zoono Room Sanitiser and Deodoriser, and Zoono Femme Hygiene. The Company’s products are applied in areas, including hospitals, medical facilities, laboratories, veterinary, homes, poultry and food processing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 21 Jul 1988
- Employees
- 2
- Website
- goldsearch.com ↗
Leadership
Pay as last reported
- Mr. Paul RavlichChief Financial OfficerNZD 273,798
- Mr. Lewis MackinnonGroup Chief Operating OfficerNZD 183,069
- Mr. Paul HyslopManaging Director, Executive Director, since 2017NZD 300,000
- Ms. Elissa HansenCompany Secretary, Independent Non-Executive DirectorNZD 83,732
- Mr. Don ClarkeIndependent Non-Executive DirectorNZD 83,732
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zoono Group Ltd has a strong intellectual property portfolio, with multiple patents and trademarks, providing a competitive advantage in the market. This robust IP protection allows the company to maintain exclusivity over its unique products.
- The company has a diverse and innovative product range, offering a wide variety of antimicrobial solutions that cater to different industries and applications. This versatility enables Zoono Group Ltd to effectively target multiple market segments and meet various customer needs.
Weaknesses
- Zoono Group Ltd is relatively smaller in size compared to some of its competitors, which limits its financial resources and market reach. This can pose challenges in terms of expanding operations, conducting extensive research and development, and penetrating new markets.
- The company heavily relies on third-party distributors and resellers to sell its products, which can result in reduced control over the sales process and potential inconsistencies in brand representation. This dependency exposes Zoono Group Ltd to risks associated with the performance and reliability of its distribution channels.
Opportunities
- Growing global concern over hygiene and infectious diseases presents a significant opportunity for Zoono Group Ltd to capitalize on its antimicrobial solutions. The company can leverage this increasing demand to expand its customer base and penetrate new industries, such as healthcare, transportation, hospitality, and food processing.
- Incorporating its antimicrobial technology into various consumer products, such as personal care items, clothing, and household goods, can open up new revenue streams for Zoono Group Ltd. By partnering with established brands, the company can enhance its market visibility and boost product adoption.
Threats
- Intense competition within the antimicrobial industry poses a threat to Zoono Group Ltd. Other companies, including both large multinational corporations and smaller startups, are continuously developing and marketing their own antimicrobial solutions, potentially eroding Zoono's market share.
- Regulatory compliance and approvals can present challenges for Zoono Group Ltd, as antimicrobial products are subject to stringent testing and certification processes. Delays or failures in obtaining necessary approvals may hinder the company's ability to launch new products or enter specific markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.